Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 142

1.

Current Options for the Pharmacotherapy of Obesity.

Gouni-Berthold I, Berthold HK.

Curr Pharm Des. 2019 Jul 8. doi: 10.2174/1381612825666190708192630. [Epub ahead of print]

PMID:
31298150
2.

The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.

Aparicio-Siegmund S, Garbers Y, Flynn CM, Waetzig GH, Gouni-Berthold I, Krone W, Berthold HK, Laudes M, Rose-John S, Garbers C.

Am J Physiol Endocrinol Metab. 2019 Aug 1;317(2):E411-E420. doi: 10.1152/ajpendo.00166.2019. Epub 2019 Jun 25.

PMID:
31237452
3.

Vitamin D supplementation of 4000 IU daily and cardiac function in patients with advanced heart failure: The EVITA trial.

Zittermann A, Ernst JB, Prokop S, Fuchs U, Gruszka A, Dreier J, Kuhn J, Knabbe C, Berthold HK, Gouni-Berthold I, Pilz S, Gummert JF, Paluszkiewicz L.

Int J Cardiol. 2019 Apr 1;280:117-123. doi: 10.1016/j.ijcard.2019.01.027. Epub 2019 Jan 9.

PMID:
30654912
4.

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.

O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS.

Circulation. 2019 Mar 19;139(12):1483-1492. doi: 10.1161/CIRCULATIONAHA.118.037184.

5.

Daily Supplementation with 4000 IU Vitamin D3 for Three Years Does Not Modify Cardiovascular Risk Markers in Patients with Advanced Heart Failure: The Effect of Vitamin D on Mortality in Heart Failure Trial.

Zittermann A, Ernst JB, Prokop S, Fuchs U, Dreier J, Kuhn J, Knabbe C, Börgermann J, Berthold HK, Pilz S, Gouni-Berthold I, Gummert JF.

Ann Nutr Metab. 2019;74(1):62-68. doi: 10.1159/000495662. Epub 2018 Dec 14.

PMID:
30554193
6.

Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score.

Moulin P, Dufour R, Averna M, Arca M, Cefalù AB, Noto D, D'Erasmo L, Di Costanzo A, Marçais C, Walther LAA, Banach M, Borén J, Cramb R, Gouni-Berthold I, Hughes E, Johnson C, Pintó X, Reiner Ž, van Lennep JR, Soran H, Stefanutti C, Stroes E, Bruckert E.

Data Brief. 2018 Oct 27;21:1334-1336. doi: 10.1016/j.dib.2018.10.125. eCollection 2018 Dec.

7.

Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.

Schmidt N, Dressel A, Grammer TB, Gouni-Berthold I, Julius U, Kassner U, Klose G, König C, Koenig W, Otte B, Parhofer KG, Reinhard W, Schatz U, Schunkert H, Steinhagen-Thiessen E, Vogt A, Laufs U, März W.

Atherosclerosis. 2018 Oct;277:314-322. doi: 10.1016/j.atherosclerosis.2018.08.050.

8.

Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial.

Zittermann A, Ernst JB, Prokop S, Fuchs U, Dreier J, Kuhn J, Knabbe C, Börgermann J, Berthold HK, Pilz S, Gouni-Berthold I, Gummert JF.

Int J Endocrinol. 2018 Jul 3;2018:5015417. doi: 10.1155/2018/5015417. eCollection 2018.

9.

Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".

Moulin P, Dufour R, Averna M, Arca M, Cefalù AB, Noto D, D'Erasmo L, Di Costanzo A, Marçais C, Alvarez-Sala Walther LA, Banach M, Borén J, Cramb R, Gouni-Berthold I, Hughes E, Johnson C, Pintó X, Reiner Ž, van Lennep JR, Soran H, Stefanutti C, Stroes E, Bruckert E.

Atherosclerosis. 2018 Aug;275:265-272. doi: 10.1016/j.atherosclerosis.2018.06.814. Epub 2018 Jun 18. Review.

10.

Large-scale deletions of the ABCA1 gene in patients with hypoalphalipoproteinemia.

Dron JS, Wang J, Berberich AJ, Iacocca MA, Cao H, Yang P, Knoll J, Tremblay K, Brisson D, Netzer C, Gouni-Berthold I, Gaudet D, Hegele RA.

J Lipid Res. 2018 Aug;59(8):1529-1535. doi: 10.1194/jlr.P086280. Epub 2018 Jun 4.

11.

A systematic literature review comparing methods for the measurement of patient persistence and adherence.

Forbes CA, Deshpande S, Sorio-Vilela F, Kutikova L, Duffy S, Gouni-Berthold I, Hagström E.

Curr Med Res Opin. 2018 Sep;34(9):1613-1625. doi: 10.1080/03007995.2018.1477747. Epub 2018 Jun 4.

PMID:
29770718
12.

Vitamin D supplementation does not prevent the testosterone decline in males with advanced heart failure: the EVITA trial.

Zittermann A, Ernst JB, Prokop S, Fuchs U, Dreier J, Kuhn J, Knabbe C, Berthold HK, Gouni-Berthold I, Gummert JF, Börgermann J, Pilz S.

Eur J Nutr. 2019 Mar;58(2):673-680. doi: 10.1007/s00394-018-1666-5. Epub 2018 Mar 15.

PMID:
29546692
13.

Vitamin D supplementation and bone turnover in advanced heart failure: the EVITA trial.

Zittermann A, Ernst JB, Prokop S, Fuchs U, Dreier J, Kuhn J, Berthold HK, Pilz S, Gouni-Berthold I, Gummert JF.

Osteoporos Int. 2018 Mar;29(3):579-586. doi: 10.1007/s00198-017-4312-9. Epub 2017 Dec 19.

PMID:
29260292
14.

The efficacy of anti-PCSK9 antibodies: Results from recent trials.

Gouni-Berthold I.

Atheroscler Suppl. 2017 Nov;30:9-18. doi: 10.1016/j.atherosclerosissup.2017.05.030. Epub 2017 Jun 1. Review.

PMID:
29096867
15.

CaRe high - Cascade screening and registry for high cholesterol in Germany.

Schmidt N, Grammer T, Gouni-Berthold I, Julius U, Kassner U, Klose G, König C, Laufs U, Otte B, Steinhagen-Thiessen E, Wanner C, März W.

Atheroscler Suppl. 2017 Nov;30:72-76. doi: 10.1016/j.atherosclerosissup.2017.05.015. Epub 2017 Jun 1.

PMID:
29096864
16.

The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.

Gouni-Berthold I.

Atheroscler Suppl. 2017 Nov;30:19-27. doi: 10.1016/j.atherosclerosissup.2017.05.003. Epub 2017 May 31. Review.

PMID:
29096837
17.

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR.

Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-950. doi: 10.1016/S2213-8587(17)30313-3. Epub 2017 Sep 15.

18.

Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus.

Gouni-Berthold I, Hanssen R, Ravarani L, Berthold HK.

Curr Pharm Des. 2017;23(31):4573-4582. doi: 10.2174/1381612823666170609084436. Review.

PMID:
28911306
19.

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.

Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators.

Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28.

20.

Randomized supplementation of 4000 IU vitamin D3 daily vs placebo on the prevalence of anemia in advanced heart failure: the EVITA trial.

Ernst JB, Prokop S, Fuchs U, Dreier J, Kuhn J, Knabbe C, Berthold HK, Pilz S, Gouni-Berthold I, Gummert JF, Börgermann J, Zittermann A.

Nutr J. 2017 Aug 23;16(1):49. doi: 10.1186/s12937-017-0270-5.

Supplemental Content

Loading ...
Support Center